PRIMARY MEMBRANOUS NEPHROPATHY

This study tests an investigational drug called WAL0921 in adults with certain kidney diseases that cause protein in the urine. About 96 participants will receive either the drug or a placebo as an IV infusion every two weeks for 14 weeks. The goal is to see if the drug is safe a…

This study tests a newer drug, obinutuzumab, against the current standard treatment (cyclophosphamide plus steroids) for people with a kidney condition called primary membranous nephropathy. About 144 adults with moderate to severe disease will receive either the new drug or the …

This study tests a new medicine, B007, against a standard treatment (cyclosporine) for people with primary membranous nephropathy, a kidney disease that causes protein leakage. About 216 adults with confirmed disease and adequate kidney function will be randomly assigned to recei…

This study tests whether adding the drug finerenone to standard blood pressure medication can better reduce protein in the urine of people with primary membranous nephropathy, a kidney disease. About 116 adults will be split into two groups: one gets finerenone plus standard care…

This study tests a new treatment called NKX019, which uses specially engineered immune cells (CAR NK cells) to target and calm overactive immune cells that attack the kidneys. It is for people with active lupus nephritis or primary membranous nephropathy who have not responded to…

This study tests a new drug, SHR-2173, in 75 adults with primary membranous nephropathy, a kidney condition that causes protein leakage. The goal is to see if the drug can safely reduce protein in urine and improve kidney function. Participants will receive the injection and be m…

This early-stage study tests a new drug, YK012, in 72 adults with primary membranous nephropathy, a kidney disease that causes protein leakage. The main goals are to check the drug's safety and how the body processes it. Researchers will also look for early signs that the drug mi…

This study tests an experimental drug called ALXN1920 in 30 adults with primary membranous nephropathy, a kidney disease that can lead to kidney failure. Participants are at high risk for their disease getting worse. The study compares the drug to a placebo to see if it reduces p…

This study tests a new drug, felzartamab, for people with primary membranous nephropathy (PMN), a kidney disease where the body's immune system attacks the kidneys. The goal is to see if felzartamab can lower protein in the urine and protect kidney function better than the curren…

This study tests a new drug, budoprutug, in 45 adults with primary membranous nephropathy, a kidney disease where the immune system attacks the kidneys. The goal is to see if the drug is safe and can help reduce protein in the urine, a sign of kidney damage. Participants will rec…

This early-stage study tests a new injected antibody for primary membranous nephropathy, a kidney disease where the immune system attacks the kidneys. About 52 adults will receive the drug to check its safety and how well it works. The goal is to control the disease, not cure it,…

This study tests a new drug, povetacicept, against a standard treatment for primary membranous nephropathy, a kidney disease that can lead to kidney failure. About 176 adults will take part to see if the new drug can put the disease into remission more safely and effectively. The…